BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fabrizi F, Dixit V, Messa P. Hepatitis C virus and mortality among patients on dialysis: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2019;43:244-54. [PMID: 30910601 DOI: 10.1016/j.clinre.2018.10.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Rajasekaran A, Franco RA, Overton ET, McGuire BM, Towns GC, Locke JE, Sawinski DL, Bell EK. Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population. Kidney Int Rep 2021;6:1788-98. [PMID: 34307975 DOI: 10.1016/j.ekir.2021.04.015] [Reference Citation Analysis]
2 Elmowafy AY, Abbas MH, Denewar AA, Mashaly ME, Shiha G, El Wasif SM, Rostaing L, Bakr MA. The effect of anemia on the efficacy and safety of treating chronic hepatitis C infection with direct-acting antivirals in patients with chronic kidney disease. Int Urol Nephrol 2021;53:749-61. [PMID: 33111161 DOI: 10.1007/s11255-020-02656-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Fabrizi F, Cerutti R, Messa P. Updated Evidence on the Epidemiology of Hepatitis C Virus in Hemodialysis. Pathogens 2021;10:1149. [PMID: 34578181 DOI: 10.3390/pathogens10091149] [Reference Citation Analysis]
4 Ridruejo E, Garcia-Agudo R, Mendizabal M, Aoufi-Rabih S, Dixit V, Silva M, Fabrizi F. Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease. Nefrologia (Engl Ed) 2020;40:46-52. [PMID: 31229261 DOI: 10.1016/j.nefro.2019.03.013] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
5 Ji Q, Chu X, Zhou Y, Liu X, Zhao W, Ye W. Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients. J Med Virol 2021. [PMID: 34599755 DOI: 10.1002/jmv.27374] [Reference Citation Analysis]
6 Taneja S, Duseja A, Mehta M, De A, Verma N, Premkumar M, Dhiman RK, Singh V, Singh MP, Ratho RK, Ramachandran R, Kumar V, Kohli HS. Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance haemodialysis. Liver Int. 2021;41:705-709. [PMID: 33025685 DOI: 10.1111/liv.14685] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
7 Fabrizi F, Cerutti R, Messa P. An Updated View on the Antiviral Therapy of Hepatitis C in Chronic Kidney Disease. Pathogens 2021;10:1381. [PMID: 34832537 DOI: 10.3390/pathogens10111381] [Reference Citation Analysis]
8 Yu M, Huang C, Wei Y, Lin W, Lin Y, Hsu P, Hsu C, Liu TW, Lee J, Niu S, Huang J, Hung T, Yeh M, Huang C, Liang P, Hsieh M, Chen S, Huang J, Chang J, Chiu Y, Dai C, Hwang S, Chuang W. Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C). Gut. [DOI: 10.1136/gutjnl-2020-323277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Fabrizi F, Cerutti R, Dixit V, Ridruejo E. Sofosbuvir-based regimens for HCV in stage 4-stage 5 chronic kidney disease. A systematic review with meta-analysis. Nefrologia 2021:S0211-6995(21)00091-6. [PMID: 34154846 DOI: 10.1016/j.nefro.2021.01.008] [Reference Citation Analysis]
10 Lin YC, Chiu WN, Chang TS, Huang TJ, Chen MY. Liver Health Literacy and Health Status Among Adults With Hepatitis C: Implications for the Nursing Profession as Part of the 2030 Global Elimination Goal. J Nurs Scholarsh 2020;52:128-35. [PMID: 31750620 DOI: 10.1111/jnu.12533] [Reference Citation Analysis]